Incyte Corporation: Polycythemia Vera trials

The registry lists 10 Polycythemia Vera studies with Incyte Corporation as lead sponsor. 1 are open to participants now and 7 have results posted.

Phase 1 2Phase 2 5Phase 3 3No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of INCA036978 in Participants With Myeloproliferative NeoplasmsRecruitingNCT07441694Phase 1
• To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)CompletedNCT04629508Phase 2Results posted
• Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief StudyCompletedNCT01632904Phase 3Results posted
• Alternative Dosing Strategy of Ruxolitinib in Patients With MyelofibrosisCompletedNCT01445769Phase 2Results posted
• Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)CompletedNCT01348490Phase 2Results posted
• Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)CompletedNCT01243944Phase 3Results posted
• COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I TrialCompletedNCT00952289Phase 3Results posted
• Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia MyelofibrosisCompletedNCT00509899Phase 1/2Results posted
• Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)CompletedNCT02252159
• An Open Label Study of Itacitinib Administered Orally in Patients With MyelofibrosisCompletedNCT01633372Phase 2